Insmed (INSM) Retained Earnings (2010 - 2026)
Insmed (INSM) posted quarterly Retained Earnings of $4000.0 for Q1 2026, up 100.0% year-over-year from $2000.0 in Q1 2025, and up 100.0% quarter-over-quarter from -$5.6 billion in Q4 2025.
Insmed (INSM) Retained Earnings (2010 - 2026) Analysis & Trends
Insmed's Retained Earnings history runs 17 years deep, the most recent figure standing at $4000.0 for Q1 2026.
- In Q1 2026, Retained Earnings rose 100.0% year-over-year to $4000.0; the TTM figure through Mar 2026 stood at $4000.0 (up 100.0% YoY), while the FY2025 annual figure was -$5.6 billion, down 221.33% from the prior year.
- Retained Earnings for Q1 2026 stood at $4000.0, up from -$5.6 billion in the prior quarter.
- The five-year high for Retained Earnings was $6.2 billion in Q2 2025, with the low at -$5.6 billion in Q4 2025.
- The 5-year median for Retained Earnings is $2.4 billion (2022), against an average of $1.0 billion.
- Peak annual rise in Retained Earnings reached 2698324.44% in 2022, while the deepest fall reached 2536555.0% in 2022.
- Insmed's Retained Earnings stood at $756000.0 in 2022, then surged by 411736.9% to $3.1 billion in 2023, then jumped by 49.22% to $4.6 billion in 2024, then tumbled by 221.33% to -$5.6 billion in 2025, then jumped by 100.0% to $4000.0 in 2026.
- Business Quant data shows INSM's Retained Earnings at $4000.0 in Q1 2026, -$5.6 billion in Q4 2025, and $2.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 5.13 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.57 Bn |
| Mar 31, 2026 | 4,000.00 |
| Dec 31, 2025 | -5.64 Bn |
| Sep 30, 2025 | 2.00 Mn |
| Jun 30, 2025 | 6.18 Bn |
| Mar 31, 2025 | -4.62 Bn |
| Dec 31, 2024 | 4.65 Bn |
| Sep 30, 2024 | 4.61 Bn |
| Jun 30, 2024 | 3.94 Bn |
| Mar 31, 2024 | 3.14 Bn |
| Dec 31, 2023 | 3.11 Bn |
| Sep 30, 2023 | 2.97 Bn |
| Jun 30, 2023 | -3.10 Bn |
| Mar 31, 2023 | 1.08 Mn |
| Dec 31, 2022 | 756,000.00 |
| Sep 30, 2022 | -2.54 Bn |
| Jun 30, 2022 | 2.45 Bn |
| Mar 31, 2022 | 2.43 Bn |
| Dec 31, 2021 | 2.67 Bn |
| Sep 30, 2021 | 100,000.00 |